Core Insights - Continued momentum in mergers and acquisitions (M&As) is anticipated for 2026, driven by strong balance sheets and growing corporate confidence [2][5] - A broader range of sectors is expected to participate in M&A activity, moving beyond traditional leaders like financial services, technology, and healthcare [2][5] - Domestic consolidation remains a key theme as Indian corporates pursue strategic growth locally while exploring international opportunities [2][5] M&A Activity Overview - Domestic consolidation reached $104 billion in 2025, marking its strongest performance in two years, while inbound deals climbed to $30 billion [4] - Outbound deals surged to $22 billion, the highest in a decade, led by acquisitions from Tata Motors and Tega Industries [4] Shifting M&A Participants - The makeup of M&A participants is changing, with mid-cap companies increasingly entering the M&A arena, previously dominated by conglomerates [3][5] - Recent examples include Mankind Pharma's acquisition of Bharat Serums and Vaccines, Tilaknagar's purchase of the Imperial Blue brand, and Jubilant's acquisition of Hindustan Coca Cola Beverages [3][5] Inbound M&A Trends - Inbound M&A is expected to continue in sectors like financial services, consumer, and infrastructure, which remain attractive to foreign investors [3][5] - The transition from a volume-driven to a value-driven model is noted, with transaction values rising sharply despite declining deal volumes over the past three years [3][5] Notable Inbound Deals - Mitsubishi UFJ Financial Group's $4.4 billion acquisition of a 20% stake in Shriram Finance was the largest inbound deal in the financial sector this year [3][5] - Other significant investments include Emirates NBD's $3 billion investment in RBL Bank and Sumitomo Mitsui Banking Corporation's $1.6 billion injection into Yes Bank [3][5] Future Outlook - The potential privatization of IDBI Bank is highlighted, with interest from Fairfax Group and Kotak Mahindra Bank as India plans to reduce the number of public sector banks [3][5] - Dealmakers' optimism for 2026 is supported by rising disposable incomes, consumption growth, and a favorable policy environment [3][5] - Recent regulatory changes, such as allowing banks to finance M&A transactions and raising foreign direct investment limits, are expected to boost dealmaking [3][5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Telix Pharmaceuticals Ltd. securities between February 21, 2025, and August 28, 2025, about the January 9, 2026, deadline to become a lead plaintiff in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Telix securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must file with the Court by January 9, 2026 [3]. - The lawsuit alleges that defendants made materially false and misleading statements regarding Telix's progress in prostate cancer therapeutic candidates and the quality of its supply chain and partners [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4].

Vanda Pharmaceuticals said on Tuesday its drug for the prevention of motion-induced vomiting was approved by the U.S. health regulator, becoming the first treatment for the condition to receive the nod in more than 40 years. ...

Core Viewpoint - Vanda Pharmaceuticals has received FDA approval for NEREUS™ (tradipitant), marking the first new pharmacologic treatment for motion sickness in over 40 years, which is a significant advancement in managing this condition that affects a large portion of the population [1][2] Company Overview - Vanda Pharmaceuticals is a global biopharmaceutical company focused on developing innovative therapies to address unmet medical needs and improve patient lives [9] - The company is advancing tradipitant for additional indications, including gastroparesis and nausea/vomiting induced by GLP-1 receptor agonists [6][10] Product Details - NEREUS™ is an oral neurokinin-1 (NK-1) receptor antagonist approved for the prevention of vomiting induced by motion in adults [11] - The drug's mechanism of action involves potent and selective antagonism of NK-1 receptors, addressing the sensory conflict that triggers nausea and vomiting [5] Clinical Evidence - The efficacy of NEREUS™ is supported by data from three pivotal clinical trials, showing significant reductions in vomiting incidence: - In Motion Syros (n=365), vomiting incidence was 18.3–19.5% with NEREUS™ compared to 44.3% with placebo (p<0.0001) - In Motion Serifos (n=316), vomiting rates were 10.4–18.3% with NEREUS™ versus 37.7% with placebo (p=0.0014), indicating risk reductions of over 50–70% [3] Market Context - Motion sickness affects approximately 25–30% of adults in the U.S., equating to roughly 65–78 million people, with up to one-third of individuals globally being highly susceptible [5] - A significant segment of the population experiences severe symptoms that can greatly impact quality of life, with tens of millions seeking pharmacologic treatment annually [5] Future Prospects - Vanda anticipates launching NEREUS™ in the coming months and is committed to expanding its therapeutic potential across indications driven by substance P-mediated pathways [7]

Eli Lilly and Company (NYSE:LLY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. Eli Lilly (LLY) Moves Fast to Secure Lead in India’s Obesity Drug Market Eli Lilly and Company (NYSE:LLY) is moving quickly to lock in its position in India’s fast-growing obesity drug market. Cheaper generic versions are expected to arrive as early as March next year, and the window to build brand loyalty is narrowing. In a notable push, the company has even partnered with well-known Bollywood actors in ...

Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. FDA Fast-Tracks Two Merck (MRK) Drugs With Blockbuster Potential On December 17, the US Food and Drug Administration moved to fast-track reviews of two experimental Merck & Co., Inc. (NYSE:MRK) drugs with multibillion-dollar potential, according to internal documents seen by Reuters. Merck’s cholesterol pill enlicitide decanoate and its cancer therapy sacituzumab tirumotecan, also known as sac-TMT, were sel ...

Abbott Laboratories (NYSE:ABT) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. Abbott (ABT) Wins FDA Approval for Volt PFA System in AFib Treatment Courtesy of Abbott Labs On December 22, Abbott Laboratories (NYSE:ABT) said the US Food and Drug Administration has approved the company’s Volt™ PFA System to treat patients with atrial fibrillation, or AFib. The company plans to begin commercial PFA cases in the United States soon and will continue expanding sites across the European Un ...

Financial Performance - Amgen's revenue increased by 12% year-over-year to $9.6 billion in the third quarter, driven by strong sales from key products [2] - Repatha, a cholesterol treatment, generated $794 million in sales, marking a 40% increase from the previous year [2] - Tezspire, an asthma therapy, also saw revenue rise by 40% year-over-year to $377 million [2] Pipeline and Growth Prospects - The company may face growth challenges in the coming quarters due to biosimilar competition for denosumab, marketed as Prolia and Xgeva [3] - Despite potential pressures, Amgen has multiple avenues to mitigate impacts, including existing products with years of sales growth potential and an active pipeline [3] - MariTide, an investigational treatment for weight management, has advanced to phase 3 studies for obesity, type 2 diabetes, and other conditions [3] Dividend Outlook - Amgen has consistently raised its dividend since 2011, with a current forward yield of approximately 3%, significantly higher than the S&P 500 average of about 1.2% [4] - The company's cash payout ratio is near 46%, indicating potential for further dividend increases [4]

Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. Gilead (GILD) Reaches Pricing Agreement with US Government to Lower Drug Costs On December 19, Gilead Sciences, Inc. (NASDAQ:GILD) announced an agreement with the US government aimed at lowering drug costs for Americans. The move reinforces the company’s long-standing focus on US-based innovation, affordability, and global health leadership. Under the three-year agreement, Gilead agreed to all reques ...

Core Viewpoint - AIM ImmunoTech Inc. announced a stock dividend of one share for every 1,000 shares of outstanding common stock and for every outstanding option or warrant that has a right to receive stock dividends, with the record date set for January 9, 2026, and distribution on January 13, 2026 [1]. Group 1: Stock Dividend Details - The stock dividend will be issued to stockholders and holders of Alternate Securities, with fractional shares rounded down and cash distributed for any remaining fractions based on a share price of $1.305, the average price on December 29, 2025 [2]. - Stockholders will not need to take any action to receive the stock dividend, as their accounts will be credited automatically, and brokers will receive the additional shares on behalf of stockholders [3]. Group 2: Company Overview - AIM ImmunoTech Inc. is focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19, with its lead product being Ampligen (rintatolimod), a first-in-class investigational drug [4].